Balloon dilatation or debulking seems to be essential to allow successful stent implantation in calcified coronary lesions. Compared with standard balloon predilatation, debulking using high-speed rotational atherectomy (RA) is associated with higher initial procedural success albeit with higher in-stent late lumen loss at intermediate-term follow-up. Whether modified (scoring or cutting) balloons (MB) could achieve similar procedural success compared with RA is not known. In addition, whether new-generation drug-eluting stents could counterbalance the excessive neointimal proliferation triggered by RA remains to be determined.
P
ercutaneous coronary intervention (PCI) is a widely used treatment for patients with complex obstructive coronary artery disease. In elderly patients, patients with diabetes mellitus, and in those with advanced renal disease, coronary calcification is common.
1,2 PCI of calcified coronary lesions remains challenging, despite significant improvements in the available tools and techniques.
Because of resistant plaque burden and irregular lesion surface, heavily calcified stenoses are difficult to dilate adequately and may contribute to failure of stent delivery or incomplete stent expansion. [3] [4] [5] [6] PCI of calcified lesions is associated with significantly increased periprocedural complications, long-term adverse clinical events, and high rates of revascularization. 1, 2, 7 To address these challenges, lesion preparation of calcified lesions before stent implantation has been established as a prerequisite to achieve adequate results.
Rotational atherectomy (RA) can effectively modify calcified plaques. Its mechanism of action relies on removing part of the obstructive atheroma by differential cutting, facilitating balloon dilatation, plaque fracture, stent delivery, and expansion. 8, 9 In the randomized ROTAXUS trial (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease), 6 a strategy of routine lesion preparation of calcified lesions with RA before first-generation drug-eluting stent (DES) implantation was more commonly successful than standard balloon predilatation. However, in-stent late lumen loss (LLL) at 9 months was higher with RA, and restenosis rates after both techniques were still significant.
Recently, modified balloons (MB) have been used increasingly in complex coronary lesions, including ostial, diffuse, and fibrocalcific ones. These specially designed balloons have either small cutting blades (eg, Flextome Cutting Balloon; Boston Scientific Corp, Natick, MA) or nitinol spiral wires (eg, AngioSculpt Scoring Balloon; Spectranetics, Colorado Springs, CO), which apply focal concentrations of dilating force and thereby assist in luminal expansion of rigid coronary lesions. The feasibility and safety of these balloons for the treatment of complex coronary lesions have been reported with good immediate results, [10] [11] [12] but no comparative studies to other techniques exist.
To date, no randomized data are available comparing the preparation of calcified lesions with an atherectomy-based strategy versus an MB-based strategy. The aim of our study was to assess the comparative performance of both strategies in a randomized trial conducted in patients with severely calcified coronary lesions receiving current-generation DES.
METHODS

Patients and Study Design
PREPARE-CALC (Comparison of Strategies to Prepare Severely
Calcified Coronary Lesions) is a randomized controlled trial in patients with myocardial ischemia and severely calcified native coronary artery lesions. The trial was performed at 2 highvolume, experienced interventional study sites in Germany, and fully trained operators with several years of interventional experience performed the procedures. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Between September 2014 and October 2017, 200 eligible patients who gave written informed consent were randomized 1:1 to a strategy of coronary lesion preparation using MB (cutting or scoring) or RA followed by DES implantation. Patients were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. The main inclusion criteria were angiographically proven coronary artery disease; presence of anginal symptoms or reproducible ischemia in the target area by electrocardiography, functional stress testing, or fractional flow reserve; target reference vessel diameter between 2.25 and 4.0 mm; luminal diameter reduction of 50% to 100%; and severe calcification of the target lesion as defined by cineangiography (radiopacities noted without cardiac motion before contrast injection generally compromising both sides of the arterial lumen). 13 Principal exclusion criteria were myocardial infarction (MI) within 1 week, decompensated heart failure, target lesions in coronary artery bypass grafts, in-stent restenosis, and target vessel thrombus. Details of all inclusion and exclusion criteria are shown in Table I in the Data Supplement.
The study was conducted in accordance with the provisions of the Declaration of Helsinki and with the International Conference on Harmonization Good Clinical Practices. The
WHAT IS KNOWN
• Balloon dilatation or debulking is commonly performed to allow successful stent implantation in calcified coronary lesions.
• Compared with standard balloon predilatation, debulking using high-speed rotational atherectomy is associated with higher initial procedural success albeit with higher in-stent late lumen loss at intermediate-term follow-up.
WHAT THE STUDY ADDS
• This is the first randomized trial to compare lesion preparation of severely calcified coronary lesions using a modified (scoring or cutting) balloon-based strategy compared with rotational atherectomy. • Strategy success is higher with rotational atherectomy. It does not result in higher late lumen loss at 9 months when combined with a modern drugeluting stent.
• A strategy of provisional modified balloon angioplasty remains feasible, safe, and effective as long as bailout rotational atherectomy is readily available, and clinical outcome is excellent with both strategies.
institutional ethics committee of the 2 participating centers approved the trial protocol.
Randomization and Procedures
Randomization was performed through computer-generated block randomization forms for each participating center. Allocation sequence was concealed using sealed, opaque envelopes. After the patient provided a written informed consent, a numbered envelope was opened in sequence, assigning the patient to either MB predilatation or RA in a 1:1 randomization fashion. The date of randomization marked the patient's entry into the study, and the assigned interventional technique had to be performed as soon as possible.
Coronary angiography was performed according to the conventional and local standards. Percutaneous intervention was either performed in the same setting, if the patient had been consented to the study before the procedure and angiographic eligibility had been determined, or in a separate setting. In case of multivessel disease, all other vessels should have been successfully treated before the assigned treatment was applied to the target vessel(s), preferably in a separate setting.
After the decision to perform intervention, patients received 325 to 500 mg aspirin intravenously or orally (if they did not receive it within the prior 12 hours) and an oral loading dose of 600 mg clopidogrel. Alternative antiplatelet drugs, such as prasugrel or ticagrelor, were allowed but were left to the operator's discretion. Immediately before intervention, intraarterial or intravenous heparin was given to maintain an activated clotting time ≥250 seconds or 200 to 250 seconds if a GP (glycoprotein) IIb/IIIa receptor blocker had been administered. The use of GP IIb/IIIa antagonists, other antithrombotics (eg, bivalirudin), and further cardiac medications was left to the discretion of the treating physician.
Optical coherence tomography (OCT) was recommended before lesion preparation and at the end of the procedure. Preprocedural OCT results were not used for clinical decision-making. Results of the OCT analysis will be reported separately.
If the patient was randomized to lesion preparation with an MB-based strategy, predilatation with conventional balloons (compliant or noncompliant) was allowed before and after MB angioplasty to facilitate device crossing and stent placement. MB angioplasty was performed by the Flextome Cutting Balloon (Boston Scientific), the AngioSculpt Scoring Balloon (AngioScore, Inc), or the Scoreflex Scoring Balloon (OrbusNeich Medical, Inc, Hong Kong). The use of more than 1 balloon was allowed. The size of the final balloon used was chosen in a 1:1 ratio according to the vessel size. Crossover to RA was only allowed if the lesion was not crossable by any balloon, not crossable by any MB even after standard balloon predilatation, not adequately dilatable (ie, complete balloon expansion without a visible residual waist could not be achieved), or the stent could not be delivered to the lesion despite complete balloon expansion.
RA was performed by the Rotablator (Boston Scientific Scimed, Natick, MA). The burr size was selected to reach a burr/vessel ratio of 0.5 (maximum 0.7 if needed). Rotational speed ranged between 140 000-180 000 rotations per minute. The burr was parked immediately proximal to the lesion to avoid injury to the healthy vessel segment. Heparin, verapamil, and nitroglycerin were administered during RA as an intracoronary infusion, and a temporary pacemaker wire was inserted during RA of the right coronary artery and the left circumflex artery in patients with a dominant left system. Balloon dilatation after RA and before stent implantation was recommended.
Stenting was performed using a new-generation sirolimuseluting stent with a bioabsorbable polymer (Orsiro; Biotronik AG, Bülach, Switzerland). More than 1 study stent was permitted for treatment of the target lesion(s). The appropriate stent length for the target lesion should have been ≥4 mm longer than the lesion length to allow for coverage between healthy vessel segments, with adequate stent overlapping. Postdilatation was performed at the operator's discretion. On procedure completion, intracoronary nitroglycerin was administered, and final angiography of the vessel was performed in at least 2 orthogonal views that showed the target site free of foreshortening or vessel overlap.
Follow-Up and End Points
After PCI, patients were prescribed 100 mg of aspirin daily indefinitely and 75 mg of clopidogrel (or an alternative antiplatelet drug) for at least 6 months. Patients on oral anticoagulation were prescribed dual therapy with clopidogrel for at least 6 months. An electrocardiography was performed 24 hours postprocedure or before discharge, whichever occurred first. Additional 12-lead ECGs were required to document any suspicious cardiac ischemic episodes. In addition, CK (creatine kinase), CK-MB, and troponin T were measured between 6 and 24 hours postprocedure. If any biomarker elevation was noted postprocedure, additional measurements were performed, as needed. During hospital stay, patients were clinically monitored for the occurrence of any adverse events and any additional coronary interventional treatment. At 9 months, a clinic visit and a repeat coronary angiography were performed. Further clinical follow-up is planned at 1 and 2 years.
The primary end point of the trial was strategy success, defined as successful stent delivery and expansion with attainment of <20% in-stent residual stenosis of the target lesion in the presence of TIMI (Thrombolysis in Myocardial Infarction) 3 flow without crossover or stent failure. 6 The coprimary end point of the trial was in-stent LLL, defined as the difference between the postprocedure and 9-month in-stent angiographic minimal lumen diameter. Secondary end points included procedural duration, contrast dye amount, periprocedural MI, in-segment LLL (inside the stent or within 5 mm proximal or distal to the stent), binary restenosis (in-stent and in-segment), stent thrombosis, and target vessel failure at 9 months, 1 year, and 2 years. Stent thrombosis was defined as proposed by the Academic Research Consortium.
14 Target vessel failure was defined as a composite of cardiac death, target vessel-related MI, and clinically driven target vessel revascularization. Detailed end point definitions are provided in the Data Supplement. Clinical follow-up at 1 and 2 years is ongoing and will be reported when complete.
All major cardiac events (including the primary and secondary end points) were adjudicated by an independent clinical event comittee. All cases of crossover were assessed by the clinical event comittee for their conformity with the trial protocol, and only cases with a protocol-defined indication for crossover were adjudicated as such.
Quantitative Angiographic Analysis
Baseline, postprocedural, and follow-up coronary angiograms were digitally recorded and assessed off-line by the quantitative angiographic core laboratory (ISAR Research Center, Munich, Germany) with an automated edge-detection system (Qangio, version 7.3; Medis Medical Imaging Systems, the Netherlands) by independent personnel blinded to treatment allocation. Measurements were performed on cineangiograms recorded after the intracoronary administration of nitroglycerine using the same single worst-view projection at all times. The contrast-filled nontapered catheter tip was used for calibration. Quantitative analysis was performed on both the in-stent and in-segment areas (including the stented segment, as well as both 5 mm margins proximal and distal to the stent). Intraobserver variability was calculated at 0.09±0.07 mm for the measurement of vessel size. Qualitative morphological lesion characteristics were characterized by standard criteria. Coronary calcification was categorized based on the angiographic classification scheme of Mintz et al. 13 
Statistical Analysis
Our group has shown in the ROTAXUS study 6 that the end point strategy success was significantly higher in lesions pretreated with RA compared with standard balloon predilatation, particularly in severely calcified lesions (92.3% versus 71.3%; P=0.001). Assuming a strategy success rate of 90% versus 75% for lesions pretreated with RA versus lesions pretreated with MB in this study, a sample size of 200 patients (100 in each arm) was calculated to provide a power of 80% at an α level of 0.05. For the coprimary end point of LLL, assuming an LLL of 0.2 mm in both groups, an SD of 0.5 mm, a noninferiority margin of ≤0.2 mm, and an average of 1.3 lesions per patient, 6 a noninferiority sample size of 148 patients (74 in each arm) was calculated given a power of 80% at an α level of 0.05. 15 With an expected attrition rate of 20% for an angiographic end point, a total of 186 patients (93 in each arm) would be needed, who have already been accounted for in the calculation of the superiority end point. On this basis, we designed the trial to include 200 patients, with 100 patients in each group.
All statistical analyses were performed by an independent statistician. Primary and secondary end points were analyzed on an intention-to-treat basis. The coprimary end point of in-stent LLL at 9 months was also analyzed on an as-treated basis. Categorical measures were compared using a χ 2 test or Fisher exact test as required. Continuous variables were compared using a 2-sided unpaired t test or a MannWhitney U test, as appropriate. For lesion-level data, differences between groups were checked for significance with generalized estimating equations to address intrapatient correlation in patients who underwent multilesion intervention. The estimated relative risk is the ratio of the risk probabilities, and a CI was constructed based on a logarithmic transformation. Missing data were assumed to be missing at random. Prespecified subgroup analyses (stratified by age, sex, diabetes mellitus, chronic kidney disease, left ventricular function, previous bypass surgery, and lesion location) and post hoc subgroup analyses were performed, with relative risks and 95% CIs calculated together with formal tests for interaction. Event-free survival was assessed using KaplanMeier method.
All tests were 2 sided, and a P value of 0.05 was considered statistically significant. No adjustment was made for the primary and secondary end point comparisons. The steering committee had full access to all the data in the study and took responsibility for its integrity and the data analysis.
RESULTS
Baseline Clinical and Angiographic Characteristics
Of 200 patients enrolled in the study, 100 patients (75 men; 75.0±6.9 years of age) were randomized to lesion preparation with MB angioplasty (MB group) and 100 patients (77 men; 74.8±7.1 years of age) to lesion preparation with RA (RA group). The study flowchart is summarized in Figure 1 . There were no significant differences between both groups with respect to clinical presentation (mostly stable angina), cardiovascular risk factors, prevalence of chronic renal failure, or history of coronary interventions (Table 1) . Multivessel disease was common and was present in the majority of patients in both groups.
Overall, 278 lesions were treated (1.39 lesions per patient): 137 in the MB group and 141 in the RA group. Patients were well balanced with respect to lesion location and morphology (Table 2) , with the majority of lesions located in the left anterior descending coronary artery. The target lesions were of high-grade stenosis (mean diameter stenosis by visual estimate 83.54±8.76% in the MB group and 83.02±10.35% in the RA group) and had several criteria signifying lesion complexity in addition to severe calcification (33.4% with moderate or severe tortuosity, 41.7% located at bifurcations, and 26.9% ostial lesions), resulting in 95.6% of lesions categorized as type B2/C according to the American College of Cardiology/American Heart Association classification. Lesion characteristics were well balanced between both study groups.
Procedural Details
Procedural details are shown in Table 2 . Almost all procedures (n=199) were performed through the femoral access route. Most procedures (86.6%) were performed through a 7F guiding catheter, although more procedures in the MB group were performed with smaller sized catheters. Unfractionated heparin was used in the majority of procedures, and the median dose was 7500 IU (range, 4000-20 000), with no significant differences between groups. The use of a GP IIb/IIIa inhibitor was rare (2 patients in the RA group).
Balloon predilatation (before or after MB and after RA) was performed in the majority of lesions using mostly (87.0%) noncompliant balloons, with a similar mean balloon size and mean inflation pressure in both groups ( Table 2 ). The use of more than 1 predilatation balloon was numerically more common in the MB group (46.6% versus 35.3%; P=0.08). In the MB group, the Angiosculpt scoring balloon was the most frequently used device (83.8%), followed by the Scoreflex scoring balloon (12.9%) and the Flextome cutting balloon (3.3%). The MB balloon had a mean diameter of 2.94±0.34 mm, a mean length of 10.59±2.33 mm, and was inflated at a mean pressure of 15.6±3.0 atm. For RA, a single burr was used in most lesions (95.1%) with a mean burr size of 1.52±0.16 mm. The mean stent length/lesion was well beyond the mean lesion length. All but 4 lesions (98.5%) were treated with the protocolassigned stent. After stenting, balloon postdilatation was performed for the vast majority (82.0%) of treated lesions in both groups, with the mean maximum postdilatation pressure slightly but not significantly higher in the MB group (21.85±4.64 versus 20.94±4.88 atm; P=0.12).
Procedural Outcome
Procedural complications and outcome are shown in Table 3 . Large coronary dissections, perforations, and no/slow-flow phenomena were rare and were not significantly different in both groups. Periprocedural side branch compromise was twofold higher in the MB group compared with the RA group (13.0% versus 6.0%), but the difference was not statistically significant (P=0.09). Fluoroscopy time was significantly longer in the RA group, with no significant differences in total procedural time or the amount of contrast dye between both groups. Strategy success, the primary end point of the trial, was significantly more common in the RA group (81% in the MB group versus 98% in the RA group; relative risk of failure with an MB-versus RA-based strategy, 9.5; 95% CI, 2.3-39.7; P=0.0001). The main driving factor for strategy failure was the need to crossover to RA in the MB group (16% versus 0%; P<0.0001). The reasons for crossing over in the MB group are detailed in Table II in the Data Supplement. Crossing over to RA was most commonly because of uncrossable (n=8) or undilatable (n=6) lesions.
Results with respect to the primary end point were consistent in the majority of prespecified and post hoc subgroups (Figure 2) . The difference between both strategies was attenuated in the following subgroups: female patients, left anterior descending coronary artery as target vessel, stenosis severity <80%, and non-type C lesions. Allowing for centers as a random effect made little difference to the results of the primary end point (P for superiority remained at 0.0001).
In-Hospital Events
There were no deaths or reinterventions during hospitalization. The incidence of protocol-defined periprocedural MI was low and not significantly different in both groups (1% in the MB group versus 2% in the RA group). Postprocedural CK, CK-MB, and troponin T levels (24 hours post-PCI) were analyzed in 198, 154, and 161 patients, respectively. The median values of all 3 markers were not significantly different between 
Quantitative Angiographic Analysis
Details of baseline quantitative coronary angiographic analysis are listed in Table 4 . Baseline minimal lumen diameter was slightly but not significantly smaller in the MB group. In general, vessel size was smaller and lesion length shorter compared with the visual estimation provided by the operators, with no significant differences between both study groups. Although severe calcification was an entry criterion for the study, the angiographic core laboratory adjudicated 25% of treated lesions as moderately calcified, with no significant differences between both groups. After treatment, no significant differences were observed in residual diameter stenosis or acute lumen gain between patients randomized to MB versus RA (Table 4 ). The 9-month angiographic follow-up is based on 160 patients (80%); 84 patients (112 lesions) randomized to the MB group and 76 patients (97 lesions) randomized to the RA group. The median time to follow-up angiography was not different between both groups (275; interquartile range, 261-285 versus 277 [270-291] days, respectively; P=0.35). The only difference observed between patients with and without angiographic follow-up is that the latter were older (77.1±5.4 versus 74.3±7.2 years; P=0.009). Details of the follow-up quantitative coronary angiographic analysis are shown in Table III in the Data Supplement. At 9 months, mean in-stent LLL (the coprimary end point) was 0.16±0.39 mm in the MB group and 0.22±0.40 mm in the RA group (P=0.21; Figure 3 ). The estimated mean difference in LLL between the MB and RA group was 0.075 mm, with a 95% CI of −0.04 to 0.19 mm, which did not exceed the predefined margin of 0.20 Subgroup analyses are shown for the primary end point of strategy success among patients who were randomly assigned to undergo lesion preparation with either a modified balloon or rotational atherectomy. The P value for interaction represents the likelihood of interaction between the variable and the relative treatment effect. Risk ratios are for rotational atherectomy versus modified balloon. CABG indicates coronary artery bypass graft; GFR, glomerular filtration rate; and LV, left ventricle. mm. Therefore, noninferiority for the coprimary end point was met at a P value of 0.02. The results were consistent in an as-treated analysis, although LLL in the MB group was slightly lower (0.14±0.40 versus 0.22±0.39 mm; P=0.16). Binary restenosis (both instent and in-segment) was low and not significantly different between both groups.
Nine-Month Clinical Outcome
Complete clinical follow-up over 9 months was available for all 200 patients (100%). At 9 months, overall mortality was 2% in both groups (P=1.00). Between discharge and 9 months, spontaneous myocardial infarction occurred in 2 patients in the MB group and none in the RA group. Clinically indicated target vessel revascularization was twice as high in the MB group, but the event rates were low and statistically not significantly different between both groups (6% versus 3%; P=0.50). Cumulative incidence curves for the secondary end point of target vessel failure are shown in Figure I in the Data Supplement. No cases of stent thrombosis were observed in both groups (Table 5) .
DISCUSSION
To our knowledge, PREPARE-CALC is the second randomized clinical trial comparing different strategies for lesion preparation in patients with calcified coronary artery disease treated with DES and the first randomized trial to compare an MB-based strategy with a strategy of RA. In an elderly population with complex calcific atherosclerotic disease treated at 2 experienced PCI centers, the primary end point of strategy success was higher with RA, which was mainly attributed to a higher frequency of crossover and stent failure in the MB group. Compared with lesion preparation with an MB, RA did not result in higher LLL at 9 months when combined with a modern DES, and clinical outcome was excellent with both strategies with low mortality, MI, and target vessel revascularization rates. Cumulative frequency curves of the coprimary end point of in-stent late lumen loss at 9-mo follow-up angiography in both study groups.
Severe coronary calcification is encountered in up to 20% of patients treated with PCI, 1 with an even higher prevalence in certain patient subgroups, particularly the elderly and those with extensive atherosclerotic disease. Clinical practice guidelines emphasize the importance of lesion preparation before attempting stent implantation for a variety of reasons: calcium often impairs balloon advancement, prevents adequate balloon dilatation, impairs stent delivery, damages stent struts or polymeric coatings during vigorous stent advancement, and prevents adequate stent expansion and apposition. [1] [2] [3] 16, 17 Therefore, PCI of calcified coronary lesions is usually more complex and time consuming and may be associated with higher periprocedural and long-term complications if procedures are not adequately planned and executed.
1,2 A variety of tools and techniques are currently available for lesion preparation, including standard balloons (compliant and noncompliant), MB (cutting and scoring), the recently introduced lithoplasty balloon, as well as atheroablative techniques, such as rotational, orbital, and laser atherectomy. The choice between these different strategies is largely dependent on their availability and on operator preference and experience, with no well-defined criteria that favor one technique over the other. In this setting, assessing the feasibility, safety, and efficacy of these different techniques in the context of a randomized controlled trial is of clinical interest.
Strategy success is an outcome measure meant to characterize the success of lesion preparation and ultimately stent implantation with a certain PCI strategy and is thus an appropriate end point for the comparative evaluation of the feasibility of different tools and techniques. Theoretically, including crossovers from one group to the other in the composite primary end point may be considered a source of bias. However, assessing the success of a balloon-based strategy justifies the inclusion of crossovers as an important measure of strategic failure. In addition, indications for crossovers were clearly defined in the trial protocol and independently adjudicated by the event committee. In our trial, a strategy of predilatation with an MB failed in almost 20% of attempted procedures. The majority of these failures were because of the inability of the balloon to reach the target lesion or to completely expand inside the calcified rigid plaque, and the procedures could only be successfully completed with bailout atherectomy. This can be partly explained by the difficulties associated with MB delivery because of its higher crossing profile, 16 although the majority of procedures were performed with the more flexible and deliverable scoring balloon, and predilatation with low-profile balloons to allow subsequent passage of the MB was allowed and commonly adopted by the treating cardiologist. On the contrary, virtually all patients (and lesions) were treatable with RA. No crossover to balloon dilatation was encountered, and the only 2 cases of strategy failure with RA were because of extensive wire-induced dissection preventing further percutaneous treatment in one case and stent failure in the other case. This finding signifies the feasibility of RA in nearly every calcified lesion, although the feasibility in chronic total occlusions cannot be assessed from this trial because of the low number of included patients.
Although RA seems to be successful in almost all calcified lesions, the procedure requires more fluoroscopy time and is usually longer than a balloon-based PCI procedure-a finding that was also observed in the ROTAXUS trial. 6 In addition, the technique is somewhat different to standard PCI and requires additional training and experience. Because 80% of patients with severe calcification are treatable with MB, characterizing the subgroup that is only treatable with atherectomy remains of clinical significance. Crossing-over to RA enables procedural success but may be associated with longer procedural time, increased procedural costs, and higher periprocedural complications. 18, 19 Despite the consistent finding of a higher strategy success with RA in the majority of patient and lesion subsets in this trial, subgroup analysis suggests that male patients, lesions located in the right coronary artery or left circumflex artery, severe (≥80%), and type C lesions more often require RA compared with female patients, lesions located in the left anterior descending coronary artery, less severe (<80%), and type B2 lesions. However, further assessment of factors associated with bailout RA is necessary and may be enhanced by intravascular imaging. Previous small studies using intravascular ultrasound and more recently OCT suggest optimal stent expansion is better achieved if calcified plaques are fractured before stent implantation. 9, 20 In this trial, OCT was recommended before lesion preparation and at the end of the PCI procedure and was performed in the majority of treated lesions. Analysis of this subgroup is planned and may give further mechanistic insights into the criteria of success of both MB-and RA-based strategies in this setting.
We observed a low rate of procedural complications, which supports the safety of both strategies considering the complexity of treated patients and anatomies. However, the pattern of complications goes in the expected direction, with numerically more dissections and side branch compromise in the MB arm and more slow-flow and pericardial effusions in the RA arm, which can be explained by the different mechanism of action of both techniques (plaque laceration versus removal). This may also explain the significantly higher number of implanted stents per lesion in the MB group. One of 3 pericardial effusions in the RA group was induced by a transient pacemaker lead introduced during atherectomy of the right coronary artery, which is a common practice but might not be necessary in all patients as recently recommended. 8 However, and despite procedural complexity, clinical events during the in-hospital period were rare, and periprocedural MI was uncommon. Although the effect of center and operator experience cannot be determined from this study, treatment of heavily calcified lesions requires special techniques, and, in elective cases, should probably be performed in a well-equipped setting to facilitate the achievement of similar outcomes.
One of the interesting findings in this trial is the excellent acute luminal gain achieved with MB, which was not significantly different from that obtained with RA. Previous trials have consistently shown a higher acute gain with RA compared with standard balloon angioplasty, 6, 21, 22 signifying more complete vessel preparation and better lumen/stent expansion. The design of cutting and scoring balloons and their focused force expansion appears to allow more consistent dilatation of rigid atherosclerotic lesions in a way that seems to allow similar stent expansion compared with RA. If the MB is able to cross and expand, final luminal gain is comparable with atherectomy.
The main drawback of RA in previous trials was its association with an exaggerated neointimal response probably triggered by thermal injury and resulting in higher rates of revascularization compared with balloon angioplasty. 21, 22 In ROTAXUS, and despite the higher acute gain, LLL after RA followed by implantation of a first-generation DES (TAXUS; Boston Scientific) was significantly higher compared with standard balloon predilatation. 6 In PREPARE-CALC, RA was, for the first time, not associated with excessive neointimal response, with a low LLL that is noninferior compared with the control arm. This observation may be explained by the cotreatment with a modern ultrathin strut sirolimuseluting stent with a biodegradable polymer (Orsiro), which has been previously associated with favorably low rates of target lesion revascularization and stent thrombosis and even lower target vessel failure rates compared with everolimus-eluting stents. 23 The advantages of this stent in the setting of severe coronary calcification are probably twofold: first, the stent backbone provides flexibility and deliverability in severely calcified lesions with a double-helix stent design and ultrathin struts 24 ; second, its superior efficacy in inhibiting neointimal response appears to counterbalance the effects of thermal injury thereby neutralizing its effect on restenosis.
Overall, the clinical event rates in this trial at 9 months are low, particularly when compared with previous trials with similar patient and lesion complexity. 6, 25, 26 This may be explained by the profile of included patients (elderly with complex lesions but with stable coronary artery disease, preserved left ventricular function, and low incidence of atrial fibrillation) and by the success of performed interventions (aggressive lesion preparation, high rate of postdilatation, high acute gain, low residual stenosis, few periprocedural complications, and modern DES). The numerically fewer target lesion revascularization and target vessel revascularization events in the RA group are encouraging and correspond to a lower angiographic binary restenosis rate, but the trial remains underpowered to assess differences in these clinical end points.
This study has some limitations. First, it includes a cohort almost exclusively treated through the femoral access route. Although complex procedures, such as RA, often require large sized catheters and optimal guide catheter support, advances in transradial tools may allow the performance of these interventions via the radial access route as well. On the contrary, an interaction of the trial primary end points with the access route is highly unlikely. Second, the majority of cases in the MB group were performed using a scoring rather than a cutting balloon, and thus, the differential performance of the latter cannot be adequately determined from this study. MB with enhanced flexibility has been recently developed and may potentially increase success rates compared with those reported in this trial. However, even if crossover cases caused by failure of MB delivery are excluded from the trial's primary end point, strategy success remains significantly higher in the RA group (87% versus 98%; P=0.005), which undermines the superiority of RA in this setting. Finally, the trial included patients predominantly experiencing stable coronary artery disease, and, therefore, its findings cannot be applied to patients presenting with an acute coronary syndrome.
In conclusion, lesion preparation with upfront RA before DES implantation is feasible in nearly all patients with complex calcified coronary lesions and is more commonly successful as a primary strategy compared with MB. Patients treated with elective RA coupled with a modern DES do not experience excessive LLL. On the contrary, a strategy of provisional MB remains feasible, safe, and effective as long as bailout RA is readily available and may offer the advantages of compatibility with smaller sized catheters, relatively shorter procedural time, and less irradiation.
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